CA00288U1066 - Common Stock
ABCELLERA BIOLOGICS INC
NASDAQ:ABCL (7/26/2024, 7:14:33 PM)
After market: 3.28 +0.02 (+0.61%)3.26
+0.16 (+5.16%)
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 586 full-time employees. The company went IPO on 2020-12-11. The company is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. The company provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The firm uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The firm partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. The company generates a range of diverse antibodies with immunization strategies and single-cell screening.
ABCELLERA BIOLOGICS INC
2215 Yukon Street
Vancouver BRITISH COLUMBIA
P: 16045599005
Employees: 586
Website: https://www.abcellera.com/
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Wall Street analysts say this drug developer can more than double your money.
If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks.
ABCL earnings call for the period ending March 31, 2024.
Here you can normally see the latest stock twits on ABCL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: